Is Protalix Biotherapeutics outlook positive for September 2022?

PLX
 Stock
  

USD 1.05  0.01  0.96%   

While some of us are excited about healthcare space, it makes sense to break down Protalix Biotherapeutics in greater detail to make a better assessment of its actual value. We are going to cover the possibilities of making Protalix Biotherapeutics into your portfolio. Is Protalix Biotherapeutics current valuation justified? We will cover the firm valuation to give you a better outlook on taking a position in the stock.
Published over a month ago
View all stories for Protalix Biotherapeutics | View All Stories
The company has 33.4 M in debt.
On a scale of 0 to 100, Protalix Biotherapeutics holds a performance score of 8. The company holds a Beta of 0.3639, which implies possible diversification benefits within a given portfolio. Let's try to break down what Protalix's beta means in this case. As returns on the market increase, Protalix Biotherapeutics returns are expected to increase less than the market. However, during the bear market, the loss on holding Protalix Biotherapeutics will be expected to be smaller as well. Although it is important to respect Protalix Biotherapeutics current trending patterns, it is better to be realistic regarding the information on the equity's existing price patterns. The philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Protalix Biotherapeutics technical indicators, you can presently evaluate if the expected return of 0.23% will be sustainable into the future. Please employ Protalix Biotherapeutics jensen alpha, potential upside, as well as the relationship between the Potential Upside and accumulation distribution to make a quick decision on whether Protalix Biotherapeutics historical price patterns will revert.
We determine the current worth of Protalix Biotherapeutics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Protalix Biotherapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Protalix Biotherapeutics's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Protalix Biotherapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Protalix Biotherapeutics. We calculate exposure to Protalix Biotherapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Protalix Biotherapeutics's related companies.

Watch out for price decline

Please consider monitoring Protalix Biotherapeutics on a daily basis if you are holding a position in it. Protalix Biotherapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Protalix Biotherapeutics stock to be traded above the $1 level to remain listed. If Protalix Biotherapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Protalix Biotherapeutics Investment Alerts

Protalix investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Protalix Biotherapeutics performance across your portfolios.Please check all investment alerts for Protalix

Protalix Biotherapeutics Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Protalix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Protalix Biotherapeutics competition to find correlations between indicators driving the intrinsic value of Protalix.

How does Protalix utilize its cash?

To perform a cash flow analysis of Protalix Biotherapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Protalix Biotherapeutics is receiving and how much cash it distributes out in a given period. The Protalix Biotherapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Sale by Akirov Alfred of 1898 shares of Protalix Biotherapeutics

Legal trades by Protalix Biotherapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Protalix insider trading alert for sale of common stock by Akirov Alfred, the corporate stakeholder, on 20th of September 2022. This event was filed by Protalix Biotherapeutics with SEC on 2013-03-12. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

An Additional Perspective On Protalix Biotherapeutics

Protalix Biotherapeutics reported the last year's revenue of 43.12 M. Reported Net Loss for the year was (24.39 M) with profit before taxes, overhead, and interest of 22 M.

Margins Breakdown

Protalix profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Protalix Biotherapeutics itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Protalix Biotherapeutics profit margins.
Operating Margin(54.76)
EBITDA Margin(51.81)
Gross Margin54.23
Profit Margin(77.6)


Protalix Biotherapeutics Net Income Per Employee is decreasing over the last 8 years. Further, Protalix Biotherapeutics Receivables Turnover is fairly stable at the moment.

Momentum Analysis of Protalix Biotherapeutics suggests possible reversal in September

The standard deviation is down to 2.23 as of today.
As of the 15th of August 2022, Protalix Biotherapeutics holds the Coefficient Of Variation of 758.85, semi deviation of 1.77, and Risk Adjusted Performance of 0.1694. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protalix Biotherapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Protalix Biotherapeutics, which can be compared to its competitors. Please check Protalix Biotherapeutics variance and potential upside to decide if Protalix Biotherapeutics is priced some-what accurately, providing market reflects its current price of 1.24 per share. Given that Protalix Biotherapeutics is a hitting penny stock territory we advise to closely look at its total risk alpha.

The Current Takeaway on Protalix Biotherapeutics Investment

While many of the other players under the biotechnology industry are still a bit expensive, Protalix Biotherapeutics may offer a potential longer-term growth to investors. With an optimistic outlook on your 90 days horizon, it may be a good time to take over new shares of Protalix or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Protalix Biotherapeutics.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Protalix Biotherapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com